The company will use the capital from this additional round of private investment to continue to advance its multi-omic platform and expand operations in areas such as single-cell sequencing and data analytics infrastructure.

Arsenal Capital Partners, a leading private equity firm specializing in building transformational healthcare businesses, led the growth investment, which included continued support from existing investors such as Blue Ox Healthcare Partners, Deerfield Management, and Labcorp.

Epic Sciences is developing and marketing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancers. The company's liquid biopsy platform leverages proven, proprietary cell analysis capabilities as well as cell-free analysis to provide more complete, efficient analysis and clearer insights - Comprehensive Cancer Profiling. Using its full-service CAP/CLIA-accredited laboratory and research support services, Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world to improve patient outcomes.